Table 3. Univariate and multivariate analyses.
| Variable | Testosterone ≥0.5 ng/mL recovery | Testosterone ≥3.5 ng/mL recovery | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | ||||||||
| HR (95% CI) | p-value | p-valuea | HR (95% CI) | p-value | HR (95% CI) | p-value | p-valuea | HR (95% CI) | p-value | ||
| PSA | 0.99 (0.99–1.00) | 0.864 | >0.999 | n.s. | 0.99 (0.96–1.01) | 0.231 | >0.999 | n.s. | |||
| Age at ADT cessation | 0.96 (0.94–0.98) | <0.001 | 0.001 | 0.964 (0.944–0.984) | <0.001 | 0.93 (0.89–0.97) | <0.001 | 0.015 | 0.94 (0.90–0.98) | 0.002 | |
| Months of ADT | 0.99 (0.98–0.99) | <0.001 | <0.001 | 0.988 (0.984–0.992) | <0.001 | 0.99 (0.98–0.99) | 0.005 | 0.084 | 0.99 (0.98–0.99) | 0.011 | |
| Gleason | |||||||||||
| 6 | Ref. | Ref. | n.s. | Ref. | Ref. | n.s. | |||||
| 7 | 1.22 (0.86–1.74) | 0.260 | >0.999 | 0.99 (0.49–2.02) | 0.996 | >0.999 | |||||
| 8-10 | 1.08 (0.64–1.81) | 0.785 | >0.999 | 0.87 (0.29–2.51) | 0.792 | >0.999 | |||||
| Clinical stage | |||||||||||
| T1 | Ref. | Ref. | n.s | Ref. | Ref. | n.s. | |||||
| T2 | 0.82 (0.59–1.14) | 0.242 | >0.999 | 0.62 (0.33–1.19) | 0.151 | >0.999 | |||||
| T3–T4 | 0.65 (0.36–1.16) | 0.144 | >0.999 | 0.44 (0.13–1.50) | 0.191 | >0.999 | |||||
| LHRH agonist | |||||||||||
| Leuprolerin (Procrin®) | Ref. | Ref. | n.s. | Ref. | Ref. | ||||||
| Triptorelin (Decapeptyl®) | 0.64 (0.41–0.99) | 0.047 | 0.611 | 0.48 (0.19–1.19) | 0.113 | >0.999 | n.s. | ||||
| Leuprolerin (Eligard®) | 0.79 (0.48–1.29) | 0.341 | >0.999 | 0.92 (0.37–2.28) | 0.857 | >0.999 | |||||
| Buserelin (Suprefact®) | 0.44 (0.21–0.89) | 0.024 | 0.384 | 0.24 (0.03–1.86) | 0.174 | >0.999 | |||||
| Goserelin (Zoladex®) | 0.71 (0.46–1.08) | 0.107 | >0.999 | 0.76 (0.34–1.67) | 0.491 | >0.999 | |||||
| Leuprorelin (Lutrate®) | NA | NA | NA | NA | NA | NA | |||||
| Primary treatment | |||||||||||
| Watchful waiting | Ref. | Ref. | n.s. | Ref. | Ref. | n.s. | |||||
| LRP | 3.03 (1.08–8.56) | 0.036 | 0.540 | 4.22 (0.59–29.90) | 0.150 | >0.999 | |||||
| RRP | 0.78 (0.43–1.40) | 0.407 | >0.999 | 1.90 (0.45–8.02) | 0.383 | >0.999 | |||||
| EBRT | 0.71 (0.33–1.51) | 0.368 | >0.999 | 2.13 (0.41–10.90) | 0.366 | >0.999 | |||||
| EBRT+ADT | 0.86 (0.40–1.82) | 0.688 | >0.999 | 0.76 (0.11–5.39) | 0.784 | >0.999 | |||||
| ADT | 0.50 (0.26–0.95) | 0.036 | 0.540 | 0.58 (0.11–3.19) | 0.535 | >0.999 | |||||
| Intervals of dosage | |||||||||||
| Every 3 months | Ref. | Ref. | n.s. | Ref. | Ref. | n.s. | |||||
| Every 6 months | 1.38 (0.91–2.08) | 0.128 | >0.999 | 0.98 (0.41–2.33) | 0.960 | >0.999 | |||||
HR: hazard ratio, CI: confidence interval, PSA: prostate-specific antigen, ADT: androgen deprivation therapy, LHRH: luteinizing hormone-releasing hormone, LRP: laparoscopic radical prostatectomy, RRP: retropubic radical prostatectomy, EBRT: external beam radiotherapy, Ref.: category of reference, NA: not available, n.s.: non-significant.
aAdjust p-values for multiple comparisons in univariate analysis.